Polpharma Prospers Again On Dutch Natalizumab
Polpharma has continued to clear the path to launching biosimilar natalizumab in Europe by prevailing in a Dutch case over a patent protecting Biogen’s Tysabri multiple sclerosis brand until 2023.
Polpharma has continued to clear the path to launching biosimilar natalizumab in Europe by prevailing in a Dutch case over a patent protecting Biogen’s Tysabri multiple sclerosis brand until 2023.